A simple blood test to choose the best treatment for each patient with depression.

Introduction

Major depressive disorder affects around 300 million people globally and is the second leading cause of disability, with up to 14 years of life lost per patient and an annual burden of up to €170 billion to the EU.

Current Challenges

Despite numerous available drugs, the following challenges persist:

1. 75% of patients do not receive adequate treatment.
2. 63% try multiple medications.
3. A third do not respond after two rounds of treatment.

This trial-and-error approach is destructive to patients, time-consuming for physicians, and expensive for healthcare systems.

Innovative Solution

RxMine revolutionizes this process by combining innovative technologies:

• Stem cell technology
• Genetics
• Neurobiology
• High-throughput screening
• Machine learning

These technologies are utilized to test multiple antidepressants and screen drug effects using a patient-specific brain-in-a-dish model.

Expected Outcomes

RxMine identifies the optimal antidepressant for each patient and has the potential to:

• Reduce hospitalizations by 89%
• Decrease emergency-room visits by 71%
• Lower depression-related healthcare costs by 40%, with savings of up to €6,000 per patient per year.